BMAL1 and cancer: These time-specific drug actions were shown to occur in a tumor clock-dependent manner because genetic perturbation of BMAL1 in the cancer cells via RNAi knockdown or CRISPR genome editing abrogated the temporal response of the tumor to the drugs [17,145].